Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction
Ozaki AF, Krumholz HM, Mody FV, Tran TT, Le QT, Yokota M, Jackevicius CA. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007665. PMID: 34465124, DOI: 10.1161/circoutcomes.120.007665.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan useInsurance plan typeReduced ejection fractionHeart failureEjection fractionValsartan useCommercial plansNew York Heart Association classPA criteriaReduced ejection fraction patientsReduced ejection fraction populationPlan typeEjection fraction patientsMedicare plansEjection fraction populationCross-sectional studyProportion of plansPrescription copaymentsAssociation classCopayment amountPrimary outcomeClinical outcomesPlan populationMore prescriptionsNational Trends in the Use of Sacubitril/Valsartan
Ozaki AF, Krumholz HM, Mody FV, Jackevicius CA. National Trends in the Use of Sacubitril/Valsartan. Journal Of Cardiac Failure 2021, 27: 839-847. PMID: 34364661, DOI: 10.1016/j.cardfail.2021.05.015.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan useReduced ejection fractionValsartan useEjection fractionHeart failurePopulation-level cohort studyNational Prescription AuditEligible patientsCohort studyPrescription patternsYounger patientsPrescription auditDosage patternClinical implicationsFurther evaluationValsartanPatientsSubstantial proportionNational trendsPrescriptionGreater increaseRecent useGreater proportionUnited States